Bidard, F. C., Mayer, E. L., Park, Y. H., Janni, W., Ma, C. X., Cristofanilli, M., Bianchini, G., Kalinsky, K., Iwata, H., Chia, S. K., Brufsky, A., Fasching, P. A., Nowecki, Z., Pascual, J., Karadurmus, N., Gal-Yam, E. N., Chatterjee, A., Miralles, M. S., Bartlett, C. H., Turner, N. (2026). First-line (1L) camizestrant (CAMI) for emergent
                    <i>ESR1</i>
                    mutations (
                    <i>ESR1</i>
                    m) in advanced breast cancer (ABC): Final progression-free survival 2 (PFS2) from the phase III SERENA-6 trial.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.17_suppl.lba1007